Skip to content

Tandem Diabetes Care TNDM Common stock, shares authorized (in shares)

Common stock, shares authorized (in shares) at other companies

Insulet logo
InsuletPODD
Medtronic logo
MedtronicMDT
Abbott logo
AbbottABT
Omnicell logo
OmnicellOMCL
ICU Medical logo
ICU MedicalICUI
CareDx logo
CareDxCDNA

Other financials

Income statement

See full
Revenue$247.2M+5.5%
Gross profit$136.8M+15.5%
Operating income-$17.4M+85.6%
Net income-$20.4M+84.4%
EPS (diluted)-$0.30+84.8%

Balance sheet

See full
Cash & equivalents$179.3M+235%
Total debt$734.7M+49.0%
Total equity$132.4M-14.7%
Total assets$1.2B+25.1%

Cash flow

See full
Operating cash flow$11.1M+160%
CapEx$6.3M+111%
Free cash flow$4.8M+123%

Valuation

See full
Market cap$1.03B-23.6%
Enterprise value$1.58B-11.3%
P/S-0.4×

Profitability

See full
Gross margin54.9%+2.7pp
Operating margin-8.2%-2.9pp
Net margin-9.2%-3.1pp
FCF margin-0.8%-0.4pp

Returns & leverage

See full
Return on equity-65.7%-14.7pp
Debt / equity5.5×+2.4×
Current ratio3.6×+1.3×

Where this comes from

Reported directly by Tandem Diabetes Care in its filing.

Tagged under the XBRL concept us-gaap:CommonStockSharesAuthorized.

The official record: Tandem Diabetes Care’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Tandem Diabetes Care's common stock, shares authorized (in shares).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Tandem Diabetes Care's common stock, shares authorized (in shares)?
Tandem Diabetes Care (TNDM) reported common stock, shares authorized (in shares) of $200M in Q1 2026.
How has Tandem Diabetes Care's common stock, shares authorized (in shares) changed year-over-year?
Tandem Diabetes Care's common stock, shares authorized (in shares) decreased by 0.0% year-over-year, from $200M to $200M.
What is the long-term trend for Tandem Diabetes Care's common stock, shares authorized (in shares)?
Over 5 years (2020 to 2025), Tandem Diabetes Care's common stock, shares authorized (in shares) has grown at a 0.0% compound annual growth rate (CAGR), from $200M to $200M.